Patent Office Grants Interim Extension for Centanafadine Hydrochloride Patent
July 24, 2026
July 24, 2026
WASHINGTON, July 24 (TNSFR) -- The U.S. Department of Commerce Patent and Trademark Office granted a one-year interim extension of U.S. Patent No. 8,877,798 covering centanafadine hydrochloride drug product claims.
Otsuka Pharmaceutical Co. Ltd., Chiyoda, Tokyo, acting for patent owner Otsuka America Pharmaceutical, Inc., Hayward, California, filed the application on July 7, 2026. The agency said Food and Drug Administration regulatory review of centanafadine hydrochloride remains . . .
Otsuka Pharmaceutical Co. Ltd., Chiyoda, Tokyo, acting for patent owner Otsuka America Pharmaceutical, Inc., Hayward, California, filed the application on July 7, 2026. The agency said Food and Drug Administration regulatory review of centanafadine hydrochloride remains . . .